Zenbexus (iberdomide hydrochloride)

Where it stands

Zenbexus (iberdomide hydrochloride), from Bristol Myers Squibb, was approved by the US FDA on 2026-08-13. The official record describes it as a new medicine and lists the application as NDA221075. The dosage form is a capsule.

The records do not state the therapeutic area or the approved indication. This analysis therefore cannot say which patients the product is approved to treat, the line of therapy, the dose, or any label conditions. Those details should be taken from the FDA approval letter and prescribing information once reviewed.

Regulatory pathway and designations

The record lists two designations: New molecular entity (NME) and Priority review. The NDA number shows the product went through the US New Drug Application route. NME status means the active moiety had not previously been approved by the FDA in any product.

Priority review is an FDA designation for applications that, if approved, could offer a significant improvement in the safety or effectiveness of treatment, diagnosis or prevention of a serious condition. It shortens the review goal. Under PDUFA, the goal for an NME application is generally six months from the 60-day filing date, versus ten months for standard review. The records give no submission date, filing date or PDUFA goal date, so the actual review timeline cannot be reconstructed here.

The record shows no CHMP opinion, which is expected for a US-region entry. It contains no information on EU or other ex-US regulatory status.

Safety and pharmacovigilance

The records contain no safety information. They give no warnings, adverse event data, risk management requirements or postmarketing commitments, so none can be assessed here.

What to watch

First, obtain the full prescribing information and approval documents to confirm the indication, the dosing, any boxed warning or REMS, and any postmarketing requirements or commitments. None of these appear in the records.

Second, watch for ex-US filings. The records show nothing on EU or other submissions, and the absence of a CHMP opinion date means no EU outcome is recorded.

Third, watch for launch and access information from Bristol Myers Squibb, such as availability and labeling updates. The records give no details on any of these.